Nuclear Medicine and Biology
Volume 36, Issue 7 , Pages 711-719 , October 2009

Reproducibility of the kinetic analysis of 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography in mouse tumor models

  • Seung Jin Choi

      Affiliations

    • Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
    • ,
  • Seog Young Kim

      Affiliations

    • Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
    • ,
  • Su Jin Kim

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, South Korea
    • ,
  • Jae Sung Lee

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, South Korea
    • ,
  • Sang Ju Lee

      Affiliations

    • Department of Chemistry, Sogang University, Seoul, South Korea
    • ,
  • Soo Ah Park

      Affiliations

    • Molecular Imaging Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, South Korea
    • ,
  • Seung Jin Lee

      Affiliations

    • Molecular Imaging Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, South Korea
    • Institute for Innovative Cancer Research, Asan Medical Center, Seoul, South Korea
    • ,
  • Sung-Cheol Yun

      Affiliations

    • Department of Preventive Medicine, Center for Medical Research and Information, University of Ulsan College of Medicine, Seoul, South Korea
    • ,
  • Ki Chun Im

      Affiliations

    • Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
    • ,
  • Seung Jun Oh

      Affiliations

    • Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
    • Molecular Imaging Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, South Korea
    • ,
  • Sang-We Kim

      Affiliations

    • Division of Oncology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
    • ,
  • Jae Seung Kim

      Affiliations

    • Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
    • Molecular Imaging Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, South Korea
    • ,
  • Jin Sook Ryu

      Affiliations

    • Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
    • Molecular Imaging Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, South Korea
    • ,
  • Dae Hyuk Moon

      Affiliations

    • Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
    • Molecular Imaging Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, South Korea
    • Institute for Innovative Cancer Research, Asan Medical Center, Seoul, South Korea
    • Corresponding Author InformationCorresponding author. Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 138-736, South Korea. Tel.: +82 2 3010 4592; fax: +82 2 3010 4588.

Received 15 December 2008 ,Revised 27 March 2009 ,Accepted 14 June 2009.

References 

  1. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–216
  2. Twombly R. Criticism of tumor response criteria raises trial design questions. J Natl Cancer Inst. 2006;98:232–234
  3. Goffin J, Baral S, Tu D, Nomikos D, Seymour L. Objective responses in patients with malignant melanoma or renal cell cancer in clinical studies do not predict regulatory approval. Clin Cancer Res. 2005;11:5928–5934
  4. Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol. 1988;6:931–933
  5. Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?. Ann Oncol. 2005;16:1723–1739
  6. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334–1336
  7. Barthel H, Cleij MC, Collingridge DR, Hutchinson OC, Osman S, He Q, et al. 3′-Deoxy-3′-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res. 2003;63:3791–3798
  8. Oyama N, Ponde DE, Dence C, Kim J, Tai YC, Welch M. Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. J Nucl Med. 2004;45:519–525
  9. Waldherr C, Mellinghoff IK, Tran C, Halpern BS, Rozenqurt N, Safaei A, et al. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3′-deoxy-3′-18F-fluorothymidine PET. J Nucl Med. 2005;46:114–120
  10. Leyton J, Latigo JR, Perumal M, Dhaliwal H, He Q, Aboagye EO. Early detection of tumor response to chemotherapy by 3′-deoxy-3′-[18F]-fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res. 2005;65:4202–4210
  11. Pio BS, Park CK, Pietras R, Hsueh WA, Satyamurthy N, Pegram MD, et al. Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol. 2006;8:36–42
  12. Wieder HA, Geinitz H, Rosenberg R, Lordick F, Becker K, Stahl A, et al. PET imaging with [18F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging. 2007;34:878–883
  13. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]-fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging. 2007;34:1339–1347
  14. Buck AK, Kratochwil C, Glatting G, Juweid M, Bommer M, Tepsic D, et al. Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT. Eur J Nucl Med Mol Imaging. 2007;34:1775–1782
  15. Herrmann K, Wieder HA, Buck AK, Schöffel M, Krause BJ, Fend F, et al. Early response assessment using 3′-deoxy-3′-[18F]-fluorothymidine positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res. 2007;13:3552–3558
  16. Dittmann H, Dohmen BM, Kehlbach R, Bartusek G, Pritzkow M, Sarbia M, et al. Early changes in [18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging. 2002;29:1462–1469
  17. Perumal M, Pillai RG, Barthel H, Leyton J, Latigo JR, Forster M. Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidine synthase inhibition by positron emission tomography. Cancer Res. 2006;66:8558–8564
  18. Reske SN, Deisenhofer S. Is 3′-deoxy-3′-[18F]-fluorothymidine a better marker for tumour response than 18F-flurodeoxyglucose?. Eur J Nucl Med Mol Imaging. 2006;33:S38–S43
  19. Muzi M, Mankoff DA, Grierson JR, Wells JM, Vesselle H, Krohn KA. Kinetic modeling of 3′-deoxy-3′-fluorothymidine in somatic tumors: mathematical studies. J Nucl Med. 2005;46:371–380
  20. Muzi M, Vesselle H, Grierson JR, Mankoff DA, Schmidt RA, Peterson L, et al. Kinetic analysis of 3′-deoxy-3′-fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med. 2005;46:274–282
  21. Visvikis D, Francis D, Mulligan R, Costa DC, Croasdale I, Luthra SK, et al. Comparison of methodologies for the in vivo assessment of 18FLT utilization in colorectal cancer. Eur J Nucl Med Mol Imaging. 2004;31:169–178
  22. Shields AF, Briston DA, Chandupatla S, Douglas KA, Lawhorn-Crews J, Collins JM, et al. A simplified analysis of [18F]3′-deoxy-3′-fluorothymidine metabolism and retention. Eur J Nucl Med Mol Imaging. 2005;32:1269–1275
  23. Kim SJ, Lee JS, Im KC, Kim SY, Park SA, Lee SJ, et al. Kinetic modeling of 3′-deoxy-3′-18F-fluorothymidine (FLT) for quantitative cell proliferation imaging in subcutaneous mouse tumor models. J Nucl Med. 2008;49:2057–2066
  24. Kenny LM, Vigushin DM, Al-Nahhas A, Osman S, Luthra SK, Shousha S, et al. Quantitation of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res. 2005;65:10104–10112
  25. Kelloff GJ, Krohn KA, Larson SM, Weissleder R, Mankoff DA, Hoffman JM, et al. The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res. 2005;11:7967–7985
  26. Tseng JR, Dandekar M, Subbarayan M, Cheng Z, Park JM, Louie S, et al. Reproducibility of 3′-deoxy-3′-18F-fluorothymidine microPET studies in tumor xenografts in mice. J Nucl Med. 2005;46:1851–1857
  27. Lee SJ, Oh SJ, Chi DY, Kil HS, Kim EN, Ryu JS, et al. Simple and highly efficient synthesis of 3′-deoxy-3′-[18F]fluorothymidine using nucleophilic fluorination catalyzed by protic solvent. Eur J Nucl Med Mol Imaging. 2007;34:1406–1409
  28. Kim JS, Lee JS, Im KC, Kim SJ, Kim SY, Lee DS, et al. Performance measurement of the microPET focus 120 scanner. J Nucl Med. 2007;48:1527–1535
  29. Dandekar M, Tseng JR, Gambhir SS. Reproducibility of 18F-FDG microPET studies in mouse tumor xenografts. J Nucl Med. 2007;48:602–607
  30. Minn H, Zasady KR, Quint LE, Wahl RL. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-d-glucose uptake at PET. Radiology. 1995;196:167–173
  31. Weber WA, Ziegler SI, Thödtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med. 1999;40:1771–1777
  32. Muzi M, Spence AM, O'Sullivan F, Mankoff DA, Wells JM, Grierson JR, et al. Kinetic analysis of 3′-deoxy-3′-fluorothymidine in patients with gliomas. J Nucl Med. 2006;47:1612–1621
  33. Schiepers C, Chen W, Dahlbom M, Cloughesy T, Hoh CK, Huang SC. 18F-Fluorothymidine kinetics of malignant brain tumors. Eur J Nucl Med Mol Imaging. 2007;34:1003–1011
  34. Grierson JR, Shwartz JL, Muzi M, Jordan R, Krohn KA. Metabolism of 3′-deoxy-3′-[F-18]fluorothymidine in proliferating A549 cells: validations for positron emission tomography. Nucl Med Biol. 2004;31:829–837
  35. Taschereau R, Chatziioannou AF. Monte Carlo simulations of absorbed dose in a mouse phantom from 18-flurine compounds. Med Phys. 2007;34:1026–1036

PII: S0969-8051(09)00152-8

doi: 10.1016/j.nucmedbio.2009.06.001

Nuclear Medicine and Biology
Volume 36, Issue 7 , Pages 711-719 , October 2009

Article Tools

* Image Usage & Resolution